The AYA gap for rhabdomyosarcoma

Affiliations

¹ Division of Pediatric Hematology and Oncology, Department of Pediatric and Adolescent Medicine, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.
² Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany.

Simone Hettmer et al. Pediatr Blood Cancer. 2024 Apr.

. 2024 Apr;71(4):e30905.

doi: 10.1002/pbc.30905. Epub 2024 Feb 4.

¹ Division of Pediatric Hematology and Oncology, Department of Pediatric and Adolescent Medicine, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany.
² Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany.

No abstract available

References

1. Cronin KA, Scott S, Firth AU, et al. Annual report to the nation on the status of cancer, part 1: national cancer statistics. Cancer. 2022;128(24):4251-4284.
1. Janardan SK, Miller TP. Adolescents and young adults (AYAs) vs pediatric patients: survival, risks, and barriers to enrollment. Hematology Am Soc Hematol Educ Program. 2023;2023(1):581-586.
1. Ferrari A, Chisholm JC, Jenney M, et al. Adolescents and young adults with rhabdomyosarcoma treated in the European paediatric Soft tissue sarcoma Study Group (EpSSG) protocols: a cohort study. Lancet Child Adolesc Health. 2022;6(8):545-554.
1. Harrison D, Qumseya A, Xue W, et al. Adolescents and young adults with rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. Pediatr Blood Cancer. 2024:e30847.
1. Trama A, Botta L, Foschi R, et al. Survival of European adolescents and young adults diagnosed with cancer in 2000-07: population-based data from EUROCARE-5. Lancet Oncol. 2016;17(7):896-906.